Novel Therapeutic Strategy for Heart Failure : Molecular Mechanism underlying the Regulation of Ca^<2+> Signaling in the Heart
Novel Therapeutic Strategy for Heart Failure : Molecular Mechanism underlying the Regulation of Ca^<2+> Signaling in the Heart
批准号:
13307065
负责人:
NAGAO Taku
金额:
$34.86万
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (A)
财政年份:
2001
资助国家:
日本
项目状态:
已结题
起止时间:
2001 至 2002
中文摘要
1) H_2O_2处理可激活大鼠新生心室肌细胞G_I/G_o。我们发现H_2O_2修饰了G_<αi>的Cys^<287>和Cys^<326>。血管紧张素II刺激产生ROS,诱导MAP激酶活化。通过共表达过氧化物氧化酶II来消除ROS,可以消除血管紧张素II诱导的JNK活化,而不影响ERK或p38 MAPK活性。这些结果表明,由受体刺激产生的ROS是连接受体刺激和MARK (JNK)激活的细胞内介质。2)为了阐明Ca^<2+>通道调节剂门控调制l型Ca^<2+>通道的分子机制,我们在l型Ca^<2+>通道a_<1C>亚基中寻找DHP结合位点。我们在IIIS5-S6成孔区鉴定了两个关键残基,Phe^<1112>和Ser^<1115>。双突变体Ca^<2+>通道(F1112A/S115A)对Ca^<2+>通道激动剂不敏感,并且被Ca^<2+>通道激动剂和拮抗剂微弱阻断。我们提出了一个新的模型,通过Ca^<2+>通道调制器在Ca^<2+>通道α_<1C>亚基的成孔区结合来调制Ca^<2+>通道门控。3)研究了l型Ca^<2+>通道与ryanodine受体间特权交叉通讯的生理作用。我们发现Ca^<2+>通道作为SR Ca^<2+>含量的传感器,在APs期间通过Ca^<2+>通道控制APD和总Ca^<2+>内流,通过Ca^<2+>近端诱导Ca^<2+>释放cicr依赖性CDI产生的Ca^<2+>通道的Ca^<2+>依赖失活,以确保cicr的有效性。4)为了说明Na^+-Ca^<2+>交换器(NCX)在心脏兴奋-收缩耦合中的生理作用。我们检测了NCX敲除杂合小鼠心脏中的Ca^<2+>信号。我们发现正向模式NCX活性在SR Ca^<2+>含量的调控中起着重要的生理作用。少
英文摘要
1) Treatment with H_2O_2 activates G_I/G_o in rat neonatal ventricular myocytes. We found that H_2O_2 modifies Cys^<287> and Cys^<326> of G_<αi>. Angiotensin II stimulation generated ROS and induced the activation of MAP kinase. The elimination of ROS by the co expression of peroxiredoxn II abolished JNK activation induced by angiotensin II without affecting ERK or p38 MAPK activities. These results indicate that ROS, produced by receptor stimulation, serves as an intracellular mediator linking the receptor stimulation and the activation of MARK (JNK).2) Aiming at elucidating the molecular mechanism underlying the gating modulation of L-type Ca^<2+> channels by Ca^<2+> channel modulators, we searched for the DHP binding sites in L-type Ca^<2+> channel a_<1C> subunit. We identified the two key residues, Phe^<1112> and Ser^<1115> in IIIS5-S6 pore-forming region. The double mutant Ca^<2+> channel (F1112A/S115A) was insensitive to Ca^<2+> channel agonists, and weakly blocked by both Ca^<2+ … More > channel agonists and antagonists. We proposed a novel model for the modulation of Ca^<2+> channel gating by the binding of Ca^<2+> channel modulators at the pore-forming region of Ca^<2+> channel α_<1C> subunit.3) We investigated the physiological role of the privileged cross-communication between L-type Ca^<2+> channels and ryanodine receptors. We found that Ca^<2+> channels function as a sensor to the SR Ca^<2+> content to manipulate APD and the total Ca^<2+> influx through Ca^<2+> channels during APs, via the Ca^<2+>-dependent inactivation of Ca^<2+> channels produced by proximal Ca^<2+>-induced Ca^<2+> release CICR-dependent CDI, to ensure the efficacy of CICR.4) In order to elucidate the physiological role of Na^+-Ca^<2+> exchanger (NCX) in cardiac excitation-contraction coupling, we examined the Ca^<2+> signaling in NCX knockout heterozygous mouse heart. We found that the forward mode NCX activity plays a physiologically important role in the regulation of the SR Ca^<2+> content. Less
期刊论文(49)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
Hagiwara M. et al.: "High affinity binding of [^3H]DTZ323 to the diltiazem-binding site of L-type Ca^<2+> channels"Eur. J. Pharmacol.. (in press). (2003)
Hagiwara M.等人:“[ 3 H]DTZ323与L型Ca 2 通道的地尔硫卓结合位点的高亲和力结合”Eur。
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
Sugimoto Y. et al.: "β_1-selective agonist (-)-1-(3,4-dimethoxyphenetylamino)-3-(3,4-dihydroxy)-2-propanol[(-)-RO363] differentially interacts with key amino acids responsible for β_1-selective binding in resting and active states"J. Pharmacol. Exp. Ther.
Sugimoto Y. 等人:“β_1-选择性激动剂 (-)-1-(3,4-二甲氧基苯乙氨基)-3-(3,4-二羟基)-2-丙醇[(-)-RO363] 与关键药物有不同的相互作用在静息和活动状态下负责 β_1-选择性结合的氨基酸“J. Pharmacol. Exp. Ther.
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
Isogaya M. et al.: "Enhanced cAMP response of naturally occurring mutant of human β_3-adrenergic receptor"Jp. J. Pharmacol.. 88:(3). 314-318 (2002)
Isogaya M.等人:“人β_3-肾上腺素受体天然突变体的增强的cAMP反应”Jp.J.Pharmacol..88:(3)(2002)。
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
Yamaguchi, S. et al.: "Key roles of Phe^<1112> and Ser^<1115> in the pore-forming IIIS5-S6 linker of L-type Ca^<2+> channel α_<1C> subunit (Cav1.2) in binding of dihydropyridines and action of Ca^<2+> channel agonists"Mol.Phamracol.. (in press). (2003)
Yamaguchi, S. 等人:“Phe^<1112> 和 Ser^<1115> 在 L 型 Ca^<2+> 通道 α_<1C> 亚基的成孔 IIIS5-S6 连接子中的关键作用 (Cav1 .2)二氢吡啶的结合和Ca 2+ 通道激动剂的作用“Mol.Phamracol..(正在出版)。(2003)
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
Nishida, M., Takagahara, S., Maruyama, Y., Sugimoto, Y., Nagao, T. and Kurose, H.: "Gβγ counteracts Gα_q signaling upon β_1-adrenergic receptor stimulation"Biochem. Biophys. Res. Commun.. 291. 995-1000 (2002)
Nishida, M.、Takagahara, S.、Maruyama, Y.、Sugimoto, Y.、Nagao, T. 和 Kurose, H.:“Gβγ 对抗 β_1-肾上腺素受体刺激时的 Gα_q 信号传导”Biochem。 .291.995-1000(2002)
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
共 48 条
Role of receptor kinase in β1-adrenergic receptor signaling, and hypertrophy/heart failure
-
批准号:11557189
-
项目类别:Grant-in-Aid for Scientific Research (B).
-
资助金额:$7.3万
-
财政年份:1999
-
负责人:NAGAO Taku
-
依托单位:
Study on regulatory mechanism for cardiac contraction : seeking for therapeutic basis of heart failure.
-
批准号:10307056
-
项目类别:Grant-in-Aid for Scientific Research (A).
-
资助金额:$20.93万
-
财政年份:1998
-
负责人:NAGAO Taku
-
依托单位:
Establishment of Functional Analysis by Expressing Antibody Molecule in the Cells
-
批准号:07557151
-
项目类别:Grant-in-Aid for Scientific Research (B)
-
资助金额:$3.84万
-
财政年份:1995
-
负责人:NAGAO Taku
-
依托单位:
Analysis of effects of Ca-antagonists in pathophysiological models
-
批准号:04454530
-
项目类别:Grant-in-Aid for General Scientific Research (B)
-
资助金额:$4.29万
-
财政年份:1992
-
负责人:NAGAO Taku
-
依托单位:
Regulation by beta-adrenoceptor subtypes of cardiac function : Analysis by selective beta agonists
-
批准号:02454485
-
项目类别:Grant-in-Aid for General Scientific Research (B)
-
资助金额:$4.03万
-
财政年份:1990
-
负责人:NAGAO Taku
-
依托单位:
海外基金